Venolife gel 2,5 mg (300 UI) + 50 mg + 20 mg/g Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

venolife gel 2,5 mg (300 ui) + 50 mg + 20 mg/g

akrihin sad, combinat chimico-farmaceutic - heparinum + colecalciferol. resin. + troxerutinum - gel - 2,5 mg (300 ui) + 50 mg + 20 mg/g

Venolife gel 2,5 mg (300 UI) + 50 mg + 20 mg/g Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

venolife gel 2,5 mg (300 ui) + 50 mg + 20 mg/g

akrihin sad, combinat chimico-farmaceutic - heparinum + colecalciferol. resin. + troxerutinum - gel - 2,5 mg (300 ui) + 50 mg + 20 mg/g

Aranesp Uniunea Europeană - română - EMA (European Medicines Agency)

aranesp

amgen europe b.v. - darbepoetină alfa - anemia; cancer; kidney failure, chronic - alte preparate antianemice - tratamentul anemiei simptomatice asociate cu insuficiența renală cronică (crf) la adulți și copii. tratamentul anemiei simptomatice la pacienții adulți cu cancer non-mieloid administrează chimioterapie.

Venclyxto Uniunea Europeană - română - EMA (European Medicines Agency)

venclyxto

abbvie deutschland gmbh co. kg - venetoclax - leucemie, limfocitică, cronică, celule b - agenți antineoplazici - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

CASPOFUNGINA MYLAN 50 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

caspofungina mylan 50 mg

pharmadox healthcare, ltd - malta - caspofunginum - pulb. pt. conc. pt. sol. perf. - 50mg - antimicotice de uz sistemic alte antimicotice sistemice

CASPOFUNGINA MYLAN 70 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

caspofungina mylan 70 mg

pharmadox healthcare, ltd - malta - caspofunginum - pulb. pt. conc. pt. sol. perf. - 70mg - antimicotice de uz sistemic alte antimicotice sistemice